Answers are grounded in this paper and cite their sources.
Cutaneous human papillomavirus (HPV)-specific cell-mediated immunity in patients with cutaneous squamous cell carcinoma (SCC) remains poorly understood, particularly in organ transplant recipients (OTRs), who often develop multiple viral warts and SCC under long-term immunosuppression. This study characterized HPV E6/E7-specific T-cell responses in OTRs with SCC and compared them with immunocompetent individuals with SCC. Participants were recruited in Singapore and included OTRs with a history of post-transplant primary SCC (n=28) and immunocompetent individuals with SCC (n=10). Fifteen-mer peptides spanning the E6/E7 regions of HPV8, HPV17, HPV49, and HPV98 were synthesized, and HPV-specific T-cell responses were measured using an Enzyme-linked immune absorbent spot(ELISpot) assay. Most participants showed positive responses to CMV peptide, the positive control, with response rates of 82% in OTRs and 70% in immunocompetent participants. Among OTRs, 28.57% responded to HPV17 E6/E7 peptides and 14.29% to HPV98, while responses to HPV8 and HPV49 were lower (7.14% and 3.57% respectively). In immunocompetent participants, 20% responded to HPV17 and HPV49, 10% to HPV8, and none to HPV98. This study provides preliminary evidence that circulating T cells reactive to selected β-HPV E6/E7 peptide pools can be detected in a subset of Asian participants with cutaneous SCC, including OTRs.
No takes yet. Share an insight, caveat, or question.
Oh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: